1. Inicio
  2. Publicaciones
  3. Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients

Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients

Fecha de publicación:

Autores de CIPF

Participantes ajenos a CIPF

  • Soldevilla, B
  • Cuevas-Martin, C
  • Ibanez, C
  • Santacatterina, F
  • Alberti, MA
  • Simo, C
  • Casasnovas, C
  • Marquez-Infante, C
  • Sevilla, T
  • Pascual, SI
  • Sanchez-Arago, M
  • Cuezva, JM

Grupos de Investigación

Abstract

Objective Charcot-Marie-Tooth 1A (CMT1A) disease is the most common inherited neuropathy that lacks of therapy and of molecular markers to assess disease severity. Herein, we have pursued the identification of potential biomarkers in plasma samples and skin biopsies that could define the phenotype of CMT1A patients at mild (Mi), moderate (Mo) and severe (Se) stages of disease as assessed by the CMT neuropathy score to contribute to the understanding of CMT pathophysiology and eventually inform of the severity of the disease. Methods We have used: (i) a high-throughput untargeted metabolomic approach of plasma samples in a cohort of 42 CMT1A patients and 15 healthy controls (CRL) using ultrahigh liquid chromatography coupled to mass spectrometry and (ii) reverse phase protein microarrays to quantitate the expression of some proteins of energy metabolism and of the antioxidant response in skin biopsies of a cohort of 70 CMT1A patients and 13 healthy controls. Results The metabolomic approach identified 194 metabolites with significant differences among the four groups (Mi, Mo, Se, CRL) of samples. A multivariate Linear Discriminant Analysis model using 12 metabolites afforded the correct classification of the samples. These metabolites indicate an increase in protein catabolism and the mobilization of membrane lipids involved in signaling inflammation with severity of CMT1 A. A concurrent depletion of leucine, which is required for the biogenesis of the muscle, is also observed in the patients. Protein expression in skin biopsies indicates early loss of mitochondrial and antioxidant proteins in patients' biopsies. Conclusion The findings indicate that CMT1 A disease is associated with a metabolic state resembling inflammation and sarcopenia suggesting that it might represent a potential target to prevent the nerve and muscle wasting phenotype in these patients. The observed changes in metabolites could be useful as potential biomarkers of CMT1 A disease after appropriate validation in future longitudinal studies.

Datos de la publicación

ISSN/ISSNe:
1932-6203, 1932-6203

Plos One  PUBLIC LIBRARY SCIENCE

Tipo:
Article
Páginas:
-
PubMed:
28575008

Citas Recibidas en Web of Science: 16

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Proyectos asociados

Neurodegeneration with Brain Iron Accumulation: Clinical Assessment and Genetic Characterization by means of a Spanish Multi-Centre Research Network

Investigador Principal: CARMEN ESPINÓS ARMERO

FUNDACION LA MARATO DE TV3 . 2015

Caracterización de MORC2, nexo de unión de neuropatías hereditarias sensitivo-motoras

Investigador Principal: CARMEN ESPINÓS ARMERO

FUNDACION RAMON ARECES . 2015

Avanzar en el diagnóstico, la prognosis y la terapia de enfermedades neurodegenerativas raras

Investigador Principal: CARMEN ESPINÓS ARMERO

INSTITUTO DE SALUD CARLOS III . 2016

Compartir